{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:58:05Z","timestamp":1790114285754,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"am","delay-in-days":364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jcyt.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T08:30:05Z","timestamp":1709713805000},"page":"472-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical effects of tacrolimus blood concentrations early after allogeneic hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-7381","authenticated-orcid":false,"given":"Hiroyuki","family":"Kubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5332-1316","authenticated-orcid":false,"given":"Osamu","family":"Imataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko Hamasaki","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyuki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimitsu","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.02.002_bib0001","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2403343","article-title":"Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate","volume":"18","author":"Kanda","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0002","first-page":"2062","article-title":"Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors","volume":"96","author":"Nash","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0003","first-page":"2303","article-title":"Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation","volume":"92","author":"Ratanatharathorn","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bmt.1703097","article-title":"Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation","volume":"28","author":"Hiraoka","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1083-8791(98)50005-5","article-title":"Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation","volume":"4","author":"Wingard","year":"1998","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0006","first-page":"1018","article-title":"The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man","volume":"25","author":"Henderson","year":"1965","journal-title":"Cancer Res"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0007","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0009","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0011","first-page":"825","article-title":"consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0012","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bmt.1703271","article-title":"Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling","volume":"28","author":"Klein","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0014","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbmt.2012.09.017","article-title":"Impact of the direction of HLA mismatch on transplantation outcomes in single unrelated cord blood transplantation","volume":"19","author":"Kanda","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0016","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3390\/cancers13040613","article-title":"Effect of early post-transplantation tacrolimus concentration on the risk of acute graft-versus-host disease in allogenic stem cell transplantation","volume":"13","author":"Sharma","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0017","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bmt.2015.323","article-title":"Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation","volume":"51","author":"Ganetsky","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14052","article-title":"The stability of initial tacrolimus concentration following allogeneic hematopoietic stem cell transplantation reduces the risk of acute GVHD","volume":"34","author":"Okabe","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0019","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","article-title":"Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"116","author":"Mohty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0020","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0021","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0022","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0023","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-00457-z","article-title":"T cell regeneration after immunological injury","volume":"21","author":"Velardi","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0024","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2005-02-0509","article-title":"In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets","volume":"106","author":"Beilhack","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0026","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl. 2","key":"10.1016\/j.jcyt.2024.02.002_bib0027","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update","volume":"50","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0028","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0171-2985(96)80033-7","article-title":"Cyclophosphamide-induced immunological tolerance: an overview","volume":"195","author":"Mayumi","year":"1996","journal-title":"Immunobiology"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0029","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0030","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0031","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood.V98.10.2942","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)","volume":"98","author":"Bacigalupo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0032","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0033","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bmt.2009.151","article-title":"Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0034","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/bmt.2017.153","article-title":"Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation","volume":"52","author":"Kawamura","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0035","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41409-018-0393-0","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis","volume":"54","author":"Kumar","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0036","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0037","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bmt.1705488","article-title":"Individual patient data meta-analysis of allogeneic peripheral blood stem cell transplant vs bone marrow transplant in the management of hematological malignancies: indirect assessment of the effect of day 11 methotrexate administration","volume":"38","author":"Bensinger","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0038","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1703616","article-title":"Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease","volume":"30","author":"Kumar","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0039","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2003-02-0430","article-title":"Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000)","volume":"102","author":"Kanda","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0040","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/bmt.2014.141","article-title":"Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT","volume":"49","author":"Fuji","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0041","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0042","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.clinthera.2012.06.022","article-title":"ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis","volume":"34","author":"Kim","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.jcyt.2024.02.002_bib0044","doi-asserted-by":"crossref","first-page":"1003812","DOI":"10.3389\/fphar.2022.1003812","article-title":"Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia","volume":"13","author":"Xu","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:39:40Z","timestamp":1714469980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1465324924000483"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.02.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical effects of tacrolimus blood concentrations early after allogeneic hematopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}